文献速递其他结缔组织病系统性红斑狼疮

系统性自身免疫病中循环免疫复合物的Fcγ受体激活及CD19-CAR T细胞治疗的降低作用

Fcγ-receptor-activation by circulating immune complexes in systemic autoimmune diseases and its reduction by CD19-CAR T cell therapy.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

本研究采用报告细胞平台评估IgG自身抗体阳性结缔组织病(CTD)患者循环免疫复合物(cICs)激活Fcγ受体的生物活性,并与健康对照及IgG自身抗体阴性系统性炎症疾病(银屑病关节炎)患者比较。结果显示CTD患者cICs生物活性显著升高,且与SSc临床表型相关,CD19-CAR T细胞治疗后显著降低。

要点

  • CTD患者cICs的FcγR激活生物活性显著高于健康对照和银屑病关节炎患者。
  • SSc中抗拓扑异构酶I(Scl70)阳性、弥漫性皮肤及肺受累者cIC生物活性显著增强。
  • CD19-CAR T细胞治疗后CTD患者cICs生物活性显著降低。

核心结论

  • CTD中存在可激活FcγR的循环免疫复合物,其生物活性与临床表型和治疗结局相关。

研究设计与样本

  • 采用报告细胞平台评估cICs存在与生物活性,对IgG自身抗体阳性CTD患者进行横断面分析,对CD19-CAR T细胞治疗患者进行纵向分析。

主要发现

  • CTD患者cICs生物活性显著高于健康对照和IgG自身抗体阴性系统性炎症疾病(银屑病关节炎)患者。
  • 所有CTD患者血清中均检测到cICs,包括系统性硬化症(SSc)和原发性干燥综合征,但个体间异质性显著。
  • SSc中抗拓扑异构酶I(Scl70)阳性、弥漫性皮肤及肺受累患者cIC生物活性显著增强。
  • CD19-CAR T细胞治疗后CTD患者cICs生物活性显著降低。

临床怎么用

  • cICs的FcγR激活生物活性可作为CTD临床表型相关指标,并用于监测CD19-CAR T细胞治疗反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The role of autoantibody-producing B cells in connective tissue diseases (CTD) has recently been highlighted by the successful treatment with CD19-targeting CAR T cells. Detrimental effects of autoantibodies are linked to the formation of deposited IgG complexes and the activation of immune cells via Fcγ receptors (FcγRs). The role of circulating immune complexes (cICs) as a link between adaptive and innate immunity has remained understudied. Clinical testing of cICs has been hindered by the lack of reliable detection methods. The aim of this study was to determine the potential of IgG-containing cICs to activate FcγRs (their bioactivity) using a new detection method. METHODS: A reporter cell platform was used to assess the presence and bioactivity of cICs in IgG-autoantibody-positive CTD patients (cross-section analysis) and in patients treated with CD19-CAR T cells (longitudinal analysis). RESULTS: The bioactivity of cICs in the cohort of patients with CTDs was significantly higher compared with healthy controls and patients with IgG-autoantibody-negative systemic inflammatory disease (psoriatic arthritis). Analyses of individual diseases revealed the presence of cICs in the sera of all CTDs, including systemic sclerosis (SSc) and primary Sjögren's syndrome, although there was significant heterogeneity among individuals. Within SSc, patients positive for anti-topoisomerase-I (Scl70) autoantibodies, diffuse cutaneous and lung involvement had significantly enhanced cIC bioactivity. Finally, the bioactivity of cICs was significantly reduced in CTD patients after CD19-CAR T cell therapy. CONCLUSIONS: Our study reveals the presence of FcγR-engaging cICs in CTDs and demonstrates that the bioactivity of cICs is correlated with clinical phenotypes and treatment outcomes.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Freitag M, Kolb P, Falcone V, et al. Fcγ-receptor-activation by circulating immune complexes in systemic autoimmune diseases and its reduction by CD19-CAR T cell therapy. Rheumatology (Oxford). 2026. PMID: 41335463. doi:10.1093/rheumatology/keaf627

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。